Skip to main content
Premium Trial:

Request an Annual Quote

ProteoMedix Taking Part in $1.7M Prostate Cancer Biomarker Project


NEW YORK (GenomeWeb) – ProteoMedix said this week that it is taking part in a research project for the development of a prognostic test for prostate cancer funded by CHF1.6 million ($1.7 million) from Switzerland's Commission for Technology and Innovation.

The goal of the project is to develop an immunoassay-based risk stratification test for predicting disease aggressiveness in patients with localized prostate cancer.

While globally roughly 900,000 men are diagnosed with prostate cancer annually, many early-stage cases are non-aggressive and may not require immediate treatment. Therefore, there is significant need for prognostic tools for determining prostate cancer aggressiveness in order to avoid overtreatment.

As part of the project, the consortium, which includes groups from the Swiss Federal Institute of Technology Zurich, University Hospital Zurich, and the University of Applied Science North Western Switzerland, will further validate the prognostic potential of ProteoMedix's proprietary biomarkers.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.